Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
-
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...
-
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
-
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...
-
CLEVELAND, April 27, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid...
-
MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
-
MENLO PARK, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
-
MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...